Enorama Pharma AB (publ)

Stockholm Stock Exchange ERMA.ST

Enorama Pharma AB (publ) Free Cash Flow Yield on January 14, 2025: -22.95%

Enorama Pharma AB (publ) Free Cash Flow Yield is -22.95% on January 14, 2025, a 10.20% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Enorama Pharma AB (publ) 52-week high Free Cash Flow Yield is -11.71% on January 31, 2024, which is 49.00% above the current Free Cash Flow Yield.
Enorama Pharma AB (publ) 52-week low Free Cash Flow Yield is -43.72% on May 30, 2024, which is -90.48% below the current Free Cash Flow Yield.
Enorama Pharma AB (publ) average Free Cash Flow Yield for the last 52 weeks is -24.65%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: ERMA.ST

Enorama Pharma AB (publ)

CEO	Mr. Daniel Schroder
IPO Date	June 10, 2016
Location	Sweden
Headquarters	Södergatan 3
Employees	5
Sector	Health Care
Industries Pharmaceuticals Tobacco

Description

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.

Key trends

Past 5 years